Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

House Republican calls on Biden to have plan to counter drug trade in Afghanistan

Rep. Jim Jordan (R-Ohio) urged the Biden administration to provide a plan on how it will counter the illicit narcotics trade in Afghanistan.

Jordan, in a letter first obtained by The Hill, asked the Office of National Drug Control Policy (ONDCP) if the administration has a strategy in place to address Afghanistan’s opium and heroin trade in light of the Taliban’s takeover of the country.

“The Taliban takeover of Afghanistan due to President Biden’s reckless and chaotic withdrawal has created a power vacuum that has emboldened terrorist groups and threatened our vital national security interests. It has also led to the Taliban seizing control of the illicit drug trade in Afghanistan that will help to finance its terror activities,” Jordan said.

Source: The Hill

https://thehill.com/homenews/house/574352-house-republican-calls-on-biden-administration-to-have-plan-to-counter-drug

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!